2-diazo-1-(3,5-difluoro-phenyl)-ethanone | 165810-45-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-diazo-1-(3,5-difluoro-phenyl)-ethanone
• 英文别名: (2E)-2-diazo-1-(3,5-difluorophenyl)ethanone
• CAS: 165810-45-7
• 化学式: C₈H₄F₂N₂O
• 分子量: 182.129
• InChiKey: GFVYBUWBMFMXCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  19.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-diazo-1-(3,5-difluoro-phenyl)-ethanone 、 在 indium(III) triflate 作用下， 生成
  参考文献：
  名称：

  Novel orally active morpholine N-arylsulfonamides γ-secretase inhibitors with low CYP 3A4 liability

  摘要：

  A new class of 2,6-disubstituted morpholine N-arylsulfonamide gamma-secretase inhibitors was designed based on the introduction of a morpholine core in lieu or piperidine in our lead series. This resulted in compounds with improved CYP 3A4 profiles. Several analogs that were active at lowering Ab levels in Tg CRND8 mice upon oral administration were identified. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.055
• 作为产物：
  描述：

  3,5-二氟苯乙酮 在 N-溴代丁二酰亚胺(NBS) 、 N,N′-双(对甲苯磺酰)肼 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 0.58h， 生成 2-diazo-1-(3,5-difluoro-phenyl)-ethanone
  参考文献：
  名称：

  区域选择性构建含吡唑的脂肪族磺酰氟的级联反应

  摘要：

  开发了一种铜催化的 α-重氮羰基化合物与乙烯磺酰氟 (ESF) 的级联反应，以良好至优异的产率 (66–98%) 提供了多种高度官能化的吡唑基脂肪族磺酰氟。该转化具有广泛的底物、独特的区域选择性、高原子经济性和操作简单等特点，为直接构建含吡唑的脂肪族磺酰氟提供了一种直接的方法，将在药物化学和其他相关学科中提供巨大的应用价值。

  DOI：

  10.1039/d2ob00515h

文献信息

• Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
  申请人：Josien B. Hubert

  公开号：US20060040936A1

  公开（公告）日：2006-02-23

  This invention discloses novel gamma secretase inhibitors of the formula: wherein: L is —O—, —N(R 6 )—, —S—, —S(O)—, or —S(O 2 )—; R 1 is selected from the group consisting of aryl and heteroaryl; R 2 is selected from the group consisting of alkyl, —C(O)—Y, —X—C(O)—Y, -alkylene-X—C(O)—Y, -alkylene-C(O)—Y, -alkylene-cycloalkylene-X—C(O)—Y, -alkylene-cycloalkylene-C(O)—Y, -cycloalkylene-alkylene-X—C(O)—Y, -cycloalkylene-alkylene-C(O)—Y, -cycloalkylene-X—C(O)—Y, -cycloalkylene-C(O)—Y, -alkylene-cycloalkylene-alkylene-X—C(O)—Y, -alkylene-cycloalkylene-alkylene-C(O)—Y, aryl, and heteroaryl; R 3 is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, and alkoxyalkyl; each R 4 and R 5 is independently selected from the group consisting of H and alkyl; and Y is selected from the group consisting of —NR 8 R 9 , —N(R 6 )—(CH 2 ) b —NR 8 R 9 , aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, and arylheterocycloalkyl; or Y is selected from the group consisting of: One or more compounds of formula I, or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

  本发明公开了式如下的新型γ 分泌酶抑制剂： 其中 L是-O-、-N(R 6 )-、-S-、-S(O)-或-S(O 2 )-; R 1 选自由芳基和杂芳基组成的组； R 2 选自由烷基、-C(O)-Y、-X-C(O)-Y、-亚烷基-X-C(O)-Y、-亚烷基-C(O)-Y、-亚烷基-环亚烷基-X-C(O)-Y、-亚烷基-环亚烷基-C(O)-Y、-环亚烷基-亚烷基-X-C(O)-Y-环亚烷基-亚烷基-C(O)-Y、-环亚烷基-亚烷基-X-C(O)-Y、-环亚烷基-亚烷基-X-C(O)-Y、-亚烷基-环亚烷基-亚烷基-C(O)-Y、芳基和杂芳基； R 3 选自由芳基、杂芳基、烷基、环烷基、芳基烷基、芳基环烷基、杂芳基烷基、杂芳基环烷基、芳基杂环烷基和烷氧基烷基组成的组； 每个 R 4 和 R 5 独立选自由 H 和烷基组成的组；以及 Y 选自 -NR 8 R 9 、-N（R 6 )-(CH 2 ) b -NR 8 R 9 、芳基、杂芳基、烷基、环烷基、芳基烷基、芳基环烷基、杂芳基烷基、杂芳基环烷基和芳基杂环烷基；或 Y 选自以下组成的组 一种或多种式 I 化合物或包含此类化合物的制剂可用于治疗阿尔茨海默病等。
• [EN] SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS<br/>[FR] AMINES HETEROCYCLIQUES A SUBSTITUTION N-ARYLSULFONYLE INHIBANT LA GAMMA SECRETASE
  申请人：SCHERING CORP

  公开号：WO2006004880A3

  公开（公告）日：2007-03-08
• GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS
  申请人：THE UPJOHN COMPANY

  公开号：EP0466730A1

  公开（公告）日：1992-01-22
• SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS
  申请人：Schering Corporation

  公开号：EP1789404B1

  公开（公告）日：2010-03-24
• Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors
  申请人：Josien Hubert B.

  公开号：US20100087425A1

  公开（公告）日：2010-04-08

  This invention discloses novel gamma secretase inhibitors of the formula: wherein: L is —O—, —N(R 6 )—, —S—, —S(O)—, or —S(O 2 )—; R 1 is selected from the group consisting of aryl and heteroaryl; R 2 is selected from the group consisting of alkyl, —C(O)—Y, —X—C(O)—Y, -alkylene-X—C(O)—Y, -alkylene-C(O)—Y, -alkylene-cycloalkylene-X—C(O)—Y, -alkylene-cycloalkylene-C(O)—Y, -cycloalkylene-alkylene-X—C(O)—Y, -cycloalkylene-alkylene-C(O)—Y, -cycloalkylene-X—C(O)—Y, -cycloalkylene-C(O)—Y, -alkylene-cycloalkylene-alkylene-X—C(O)—Y, -alkylene-cycloalkylene-alkylene-C(O)—Y, aryl, and heteroaryl; R 3 is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, and alkoxyalkyl; each R 4 and R 5 is independently selected from the group consisting of H and alkyl; and Y is selected from the group consisting of —NR 8 R 9 , —N(R 6 )—(CH 2 ) b —NR 8 R 9 , aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, and aryl heterocycloalkyl; or Y is selected from the group consisting of: One or more compounds of formula I, or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.